Good
Mostly Aligned
Patient Risk:
Low
Summary
The claims largely align with the labeled safety warnings, dosing guidance, and use-of-therapy limitations. Several statements are supported by specific label sections (mortality risk warnings, hepatic effects, and monitoring). One claim is contradicted by the label, and one claim is not supported by the label (absent from label).
Category Scores
Accurate Statements
Tigecycline carries warnings tied to safety outcomes observed in clinical studies, including higher risk of death compared with some other antibiotics used for similar indications.
5.1
In studies where tigecycline was compared with other treatments for certain complicated infections, outcomes showed an imbalance favoring the comparator antibiotics in overall mortality.
5.2
Many guidelines and prescribing practices reserve tigecycline for situations where other options are less suitable.
1.4, 5.1
Beyond the mortality signal, tigecycline can cause typical antibiotic adverse effects.
6, 5.11
Patients may experience nausea and vomiting.
6, 5.11
Tigecycline can be associated with liver test abnormalities.
5.4
Tigecycline can be associated with other gastrointestinal side effects.
6, 5.11
The risk of adverse outcomes may be influenced by patient condition and infection type.
5.2
Prescribers typically monitor for treatment tolerability and lab abnormalities during therapy.
2.4, 5.4
Unsupported Statements
Contradictions
Low
AI Statement
Clinicians generally weigh tigecycline against other options, especially when treating less complicated infections or when standard therapies are likely to work.
Label Reference
1.4, 5.1
Important Omissions
Prescribers typically reassess therapy once culture results and clinical response are available, switching to a better-tolerated or more targeted antibiotic when possible.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label documents an all-cause mortality risk imbalance and hepatic adverse effects; magnitude is small but clinically relevant; safety focus includes monitoring and limiting use to situations where alternatives are not suitable.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Contradicted claim about routine weighing against alternatives for less complicated infections; label supports reserving use when alternatives are not suitable.
Suggested Improvement
Clarify standard clinical decision-making statements to reflect that tigecycline is reserved when alternative therapies are not appropriate (per 1.4) and not routinely weighed against all other options for less severe infections.